The FDA strongly recommends in-depth characterization of particles in protein therapeutics. Dynamic imaging particle analysis is being utilized because it can provide incredible insight to your formulation, allowing you to see your particles like never before, especially in the 2 to 10 micron range
In this informative Webinar, special guest presenters Dr. John Carpenter and Dr. Jeff Schwegman discuss the importance of sub-visible particle characterization in therapeutic protein formulations.
Dr. John F. Carpenter, Ph.D., Center for Pharmaceutical Biotechnology, Department of Pharmaceutical Sciences, University of Colorado Anschutz Medical Center. Dr. Carpenter will discuss the role of protein aggregates in immunogenicity and why we should care about it.
Dr. J. Jeff Schwegman, Ph.D., Founder & CEO, AB BioTechnologies. Dr. Schwegman will talk about how he uses imaging analysis as a screening tool when developing formulations.
Lew Brown, Technical Director, Fluid Imaging Technologies. Lew will review the importance of image quality for particles in the 2-10 um range.